A review has been done of the available literature on measles, mumps, rubella and vaccines against these diseases. So far, 17 studies on the same virus strains as those in M-M-R II have been published. The rate of seroconversion is practically 100% for rubella, generally more than 90% for measles and between 40 and 100% for mumps. Immediate side effects of vaccinaton are mild in infants and negligible in schoolchildren. However, the follow-up periods are short. In the only 10-year follow-up published, 14 subjects remained at the end of the period, and the vaccine studied differed from M-M-R II. Large, well-documented studies of MMR vaccination in unselected populations are rare. It must be of crucial importance that the immunity situation is followed up continuously for both vaccinated and non-vaccinated individuals when a mass vaccination programme has been introduced as there will be a risk of outbreaks of diseases mostly among young adults.
BöttigerMChristensonBHedenskogSAnslag och reaktioner efter immunisering av 18–24 månader gamla barn med kombinerat vaccin mot mässling, påssjuka och röda hund. Svenska Läkaresällskapets handlingar1982; band 91:265.
4.
ChristensonBBöttigerMHellerL.Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: First experience. Br Med J1983; 287:289–91.
5.
BöttigerMChristensonBTarangerJMass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: Vaccination of school children. Vaccine1985; 113–16.
6.
KhanjansthitiPJayavasuJKashementCSero-conversion and reaction of vaccines, rubella–mumps and measles–rubella–mumps combined. J Med Ass Thai1978; 61:536–43.
7.
SugiuraAOhtawaraMHayamiMField trial of trivalent measles–rubella–mumps vaccine in Japan. J Infect Dis1982; 146:709.
8.
VesikariTAla-LaurilaE-LHeikkinenAClinical trial of a new trivalent measles–mumps–rubella vaccine in young children. AIDS1984; 138:843–7.
9.
JustMBergerRGluckRField trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella. Schweiz Med Wochenschr1985; 115:1727–30.
10.
IsozakiMKuno-SakiHHoshiNEffects and side effects of a new trivalent combined measles—mumps–rubella (MMR) vaccine. Tokai J Exp Clin Med1982; 7:547–50.
11.
LermanSJBollingerMBrunenJM. Clinical and serologic evaluation of measles, mumps and rubella (HPV-77: DES and RA27/3) virus vaccines, singly and in combination. Pediatrics1981; 68:18–22.
12.
WeibelREBuynakEBMcLeanAALong-term follow-up for immunity after monovalent or combined live measles mumps and rubella virus vaccines. Pediatrics1975; 56:380–7.
13.
VesikariTAndreéFESimoenEComparison of the Urabe Am 9-Schwarz and Jeryl Lynn-Moraten combinations of mumps-measles-vaccines in young children. Acta Paediatr Scand1983; 72:41–6.
14.
KarchmerAWFriedmanJPCaseyHLSimultaneous administration of live virus vaccines measles, mumps, polio-myelitis and smallpox. Am J Dis Child1971; 121:82–4.
15.
RaboETarangerJ.Scandinavian model for eliminating measles, mumps and rubella. Br Med J1984; 289:1402–4.
16.
RaboE.Strategi för eliminering av mässling, påssjuka och röda hund. Läkartidningen1981; 34:2840–4.
17.
CherryJD. The “new” epidemiology of measles and rubella. Hosp Practice1980; 15:49–57.
18.
PentolaHHeinonenOP. True adverse reaction frequencies of measles–mumps–rubella vaccine. Lancet1986; 8487:939–42.
19.
NorrbyR.Polyradikulit i anslutning till vaccination mot morbilli, parotit och rubella. Läkartidningen1984; 81:636–7.
20.
NeiderudJ.Thrombocytopen purpura after a combined vaccine against morbilli, parotitis and rubella. Acta Paediatr Scand1983; 72:613–14.
21.
KazarinEIGagerWE. Optic neuritis complicating measles, mumps and rubella vaccination. Am J Ophthalmol1978; 86:544–7.
22.
BöttigerMHellerLRollofSI. Rubellavaccination av tonårsflickor. Läkartidningen1974; 71:1949–58.
23.
O'SheaSBestJBanatvalaJERubella vaccination: Persistence of antibodies for up to 16 years. Br Med J1982; 285:253–5.
24.
O'SheaSBestJMBanatvalaJE, Persistence of rubella antibody 8–18 years after vaccination. Br Med J1984; 288:1043.
25.
SuniJIMeurmanOHirvonenPVaccination with a live RA 27/3 stain rubella vaccine (Rudivax) a follow-up study. Vaccine1984; 2:281–3.
26.
HillaryIBGriffithAH. Persistence of antibody 10 years after vaccination with Wistar RA 27/3 live attenuated rubella vaccine. Br Med J1980; 280:1580–1.
27.
WeibelREBuynakEBMcLeanAAPersistence of antibody in human subject for 7 to 10 years following administration of combined live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med1980; 165:260–3.
28.
WeibelREBuynakEBMcLeanAAPersistence of antibody after administration of monovalent and combined live attenuated measles, mumps and rubella virus vaccines. Pediatrics1978; 61:5–11.
29.
Center for Disease Control.Measles outbreak among vaccinated high school students—Illinois. MMWR1984; 33:349–51.
30.
Center for Disease Control.Measles in an immunized school-aged population—New Mexico. MMWR1985; 34:52–9.
31.
HinmanARKoplanJP. Public health policy toward atypical measles syndrome in the United States. Med Decis Making1982; 2:71–7.
32.
Center for Disease Control.Death from measles, possibly atypical—Michigan. MMWR1979; 28:298–9.
33.
WeibelRICarlssonAAJrVillarejosWMClinical and lab studies of combined live measles, mumps and rubella vaccine. Proc Soc Exp Biol Med1980; 165:323–6.
34.
WeibelREBuynakEBStokesJPersistence of immunity following monovalent and combined live measles, mumps and rubella virus vaccines. Pediatrics1973; 51:467–75.
35.
MitchellCDBalfourHHJr.Measles control: So near and yet so far. Prog Med Virol1985; 31:1–42.
36.
AmlerRWKim-FarleyRJOrensteinWAMeasles on campus. J Am Coll Health1983; 32:53–7.
37.
SeidaJ.Control of measles in Czechoslovakia (CSSR). Rev Infect Dis1983; 5:564–7.
38.
BlockABOrensteinWAStetlerHCHealth impact of measles vaccination in the United States. Pediatrics1985; 76(4):524–32.
39.
PentolaHKurkiTVirtanenMRapid effect on endemic measles, mumps and rubella of nationwide vaccination programme in Finland. Lancet1986; Jan 18; (8473):137–9.
40.
JonsellRRomanusVBöttigerMVaccination mot mässling, påssjuka och röda hund. BVC: God anslutning redan under första året. Läkartidningen1984; 81:1632–3.
41.
MitusA.Vaccination of collage students with attenuated live measles vaccine. N Engl J Med1985; May 15:312 (20) 1326.
